Hello! I'd like to host a small 'let's understand Galois / group theory' meetup in SF. If you've ever spent hours sta...
A community invitation: a small meetup in San Francisco to understand Galois theory and group theory together. The post is an educational, non-market event invite with a link to the original post.
Linked assets
One open ticker listed: SF — used here to denote the San Francisco meetup/event. This is non-financial, community content.
San Francisco meetup invitation focused on Galois theory and group theory (non-financial event).
Hello! I'd like to host a small 'let's understand Galois / group theory' meetup in SF. If you've ever spent hours sta... Hello! I'd like to host a small 'let's understand Galois / group theory' meetup in SF. If you've ever spent hours staring at group theory textbook desperately trying to understand why it's relevant to polynomials - this meetup is for you! https://t.co/CgbKa4TaCE
Source proof
Source proof: Supported source proof | 1 extracted claim | 1 directional asset | 1 supporting author | headline-like title review
Primary source is a public invitation to a meetup about Galois/group theory (includes the original link https://t.co/CgbKa4TaCE). Additional related posts in the bundle are non-market content (hiring post, proof-of-concept device demo, and an anecdotal note about an FDA approval) and do not provide tradable company or financial information.
Non-market content: an invitation to a small meetup about Galois/group theory in San Francisco. No finance, macro, company, or ticker-relevant information provided.
The source is a job/engineering recruiting post for “Until” about shipping biology-transforming devices. It contains no market-relevant details (no product specs, customers, funding, timelines, partnerships, financials) and no public-company references/tickers.
Post describes a proof-of-concept device that can traverse the “danger zone” for ice formation in <1 minute while drawing only a few kW, demonstrated on a pig kidney (human-scale). If reproducible and scalable, this points to improved organ preservation/rewarming (less ice crystal damage), potentially expanding viable transplant logistics and increasing transplant volumes over time. No company/ticker is named; investability is therefore thematic and longer-horizon.
Post announces a “first FDA approval” for an (unspecified) company in the author’s portfolio, framing it as a transformative therapy. No company name, drug, indication, label, or ticker is provided in the text, so it is not directly tradable as-is.
Supporting authors
Content originates from a single public author who posted the meetup invitation. No institutional research or company disclosures are attached.
Unlock full thesis monitoring
If you’re interested in attending or learning more, follow the link in the original post to view the invitation and any RSVP details.